Patents by Inventor Lauge Schaffer

Lauge Schaffer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070265189
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: July 10, 2007
    Publication date: November 15, 2007
    Applicants: Novo Nordisk A/S, Antyra Inc.
    Inventors: Renuka Pillutla, Renee Brissette, Arthur Blume, Lauge Schaffer, Jakob Brandt, Neil Goldstein, Jane Spetzler, Soren Ostergaard, Per Hansen
  • Patent number: 6875741
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: April 5, 2005
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schäffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Søren Østergaard, Per Hertz Hansen
  • Publication number: 20030236190
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2002
    Publication date: December 25, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jacob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Publication number: 20030195147
    Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.
    Type: Application
    Filed: September 24, 2001
    Publication date: October 16, 2003
    Inventors: Renuka Pillutla, Renee Brissette, Arthur J. Blume, Lauge Schaffer, Jakob Brandt, Neil I. Goldstein, Jane Spetzler, Soren Ostergaard, Per Hertz Hansen
  • Publication number: 20030171535
    Abstract: The present invention relates to derivatives of insulin and insulin analogues wherein the N-terminal amino group of the B-chain and/or the &egr;-amino group of Lys in position B28, B29 or B30 has a substituent of the formula —CO—W—COOH wherein W is a divalent long chain hydrocarbon group having from 12 to 22 carbon atoms and zinc complexes thereof are soluble at physiological pH values and exhibit a long disappearance half-life from the injection site after subcutaneous injection.
    Type: Application
    Filed: July 2, 2002
    Publication date: September 11, 2003
    Inventors: Lauge Schaffer, Per Balschmidt
  • Patent number: 6451970
    Abstract: The present invention relates to derivatives of insulin and insulin analogues wherein the N-terminal amino group of the B-chain and/or the &egr;-amino group of Lys in position B28, B29 or B30 has a substituent of the formula —CO—W—COOH wherein W is a divalent long chain hydrocarbon group having from 12 to 22 carbon atoms and zinc complexes thereof are soluble at physiological pH values and exhibit a long disappearance half-life from the injection site after subcutaneous injection.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: September 17, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaffer, Per Balschmidt
  • Publication number: 20020045731
    Abstract: The present invention relates to derivatives of insulin and insulin analogues wherein the N-terminal amino group of the B-chain and/or the &egr;-amino group of Lys in position B28, B29 or B30 has a substituent of the formula —CO—W—COOH wherein W is a divalent long chain hydrocarbon group having from 12 to 22 carbon atoms and zinc complexes thereof are soluble at physiological pH values and exhibit a long disappearance half-life from the injection site after subcutaneous injection.
    Type: Application
    Filed: February 20, 1997
    Publication date: April 18, 2002
    Applicant: Novo Nordisk of North America, Inc.
    Inventors: LAUGE SCHAFFER, PER BALSCHMIDT
  • Publication number: 20020028767
    Abstract: Insulin derivatives having a built-in glucose sensor, capable of delivering insulin from a depot as a function of the glucose concentration in the surrounding medium (e.g. tissue), such that the rate of insulin release from the depot increases with an increased glucose concentration and decreases with a decreased glucose concentration.
    Type: Application
    Filed: May 31, 2001
    Publication date: March 7, 2002
    Inventors: Thomas Hoeg Jensen, Svend Havelund, Jan Markussen, Soren Ostergaard, Signe Ridderberg, Per Balschmidt, Lauge Schaffer, Ib Jonassen